A Phase 1 Study to Assess the Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and the Effect of Food on ALXN2050 Pharmacokinetics in Healthy Adult Participants
Latest Information Update: 21 Feb 2025
At a glance
- Drugs Vemircopan (Primary)
- Indications Autoimmune disorders; IgA nephropathy; Lupus nephritis; Myasthenia gravis; Paroxysmal nocturnal haemoglobinuria
- Focus Pharmacokinetics
- Sponsors Alexion AstraZeneca Rare Disease
Most Recent Events
- 19 Jan 2023 Status changed from active, no longer recruiting to completed.
- 03 Jan 2023 Planned End Date changed from 23 Dec 2022 to 28 Dec 2022.
- 03 Jan 2023 Planned primary completion date changed from 19 Dec 2022 to 24 Dec 2022.